David Fairmain
- PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary diseaseBy Iain Kilty, Nick Clarke, David Fairmain, David Lamb, John Mathias, David Millan, Karen Wright, Christelle Perros-Huguet and Mike YeadonIain Kilty1Inflammation & Remodelling Research Unit, Pfizer Global R&D, Cambridge, MA, United StatesNick Clarke1Inflammation & Remodelling Research Unit, Pfizer Global R&D, Cambridge, MA, United StatesDavid Fairmain2Allergy & Respiratory Research Unit, Pfizer Global R&D, Sandwich, Kent, United KingdomDavid Lamb2Allergy & Respiratory Research Unit, Pfizer Global R&D, Sandwich, Kent, United KingdomJohn Mathias1Inflammation & Remodelling Research Unit, Pfizer Global R&D, Cambridge, MA, United StatesDavid Millan2Allergy & Respiratory Research Unit, Pfizer Global R&D, Sandwich, Kent, United KingdomKaren Wright2Allergy & Respiratory Research Unit, Pfizer Global R&D, Sandwich, Kent, United KingdomChristelle Perros-Huguet1Inflammation & Remodelling Research Unit, Pfizer Global R&D, Cambridge, MA, United StatesMike Yeadon2Allergy & Respiratory Research Unit, Pfizer Global R&D, Sandwich, Kent, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.